Imatinib mesylate as second-line treatment in a c-kit-positive esthesioneuroblastoma.
S. Kim
No relevant relationships to disclose
J. R. Atta
No relevant relationships to disclose
L. Bergmann
No relevant relationships to disclose
O. G. Ottmann
No relevant relationships to disclose